Bleb Vascularity Change After Subconjunctival Injection Bevacizumab

Capital Medical University

Status and phase: Unknown; Phase 4

Conditions: Conjunctival Scarring; Bleb Vascularity

Treatments: Drug: bevacizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT00815594

2008TR-LX-001

Details and patient eligibility

About

The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Glaucoma patients after trabeculectomy whose bleb is hyperaemia

Exclusion criteria

• Affected eye has normal IOP
• Not allergic with Avastin

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)